Abstract Chinese herbal medicine has shown promise for heroin detoxification. This review extends a prior meta-analysis of Chinese herbal medicine for heroin detoxification, with particular attention to the time course of symptoms. Both English and Chinese databases were searched for randomized trials comparing Chinese herbal medicine to either a2-adrenergic agonists or opioid agonists for heroin detoxification. The methodological quality of each study was assessed with Jadad's scale (1-2 = low; 3-5 = high). Metaanalysis was performed with fixed-or random-effect models in RevMan software; outcome measures assessed were withdrawal-symptoms score, anxiety, and adverse effects of treatment. Twenty-one studies (2,949 participants) were included. For withdrawalsymptoms score relieving during the 10-day observation, Chinese herbal medicine was superior to a2-adrenergic agonists in relieving opioid-withdrawal symptoms during 4-10 days (except D8) and no difference was found within the first 3 days. Compared with opioid agonists, Chinese herbal medicine was inferior during the first 3 days, but the difference became non-significant during days 4-9. Chinese herbal medicine has better effect on anxiety relieving at late stage of intervention than a2-adrenergic agonists, and no difference with opioid agonists. The incidence of some adverse effects (fatigue, dizziness) was significantly lower for Chinese herbal medicine than for a2-adrenergic agonists (sufficient data for comparison with opioid agonists were not available). Findings were robust to file-drawer effects. Our metaanalysis suggests that Chinese herbal medicine is an effective and safety treatment for heroin detoxification. And more work is needed to determine the specific effects of specific forms of Chinese herbal medicine.
Introduction
Opioid abuse and addiction are major risk factors for disease, particularly in Asia, Europe, Oceania, and the Middle East (United Nations Office on Drugs and Crime 2007). Opioid addiction can be treated with a variety of pharmacological agents (including opioid agonists, partial opioid agonists, opioid antagonists, and a2-adrenergic agonists); the use of such agents during detoxification (managed withdrawal) and maintenance has recently been reviewed (Gonzalez et al. 2002) .
Detoxification from opioids is not itself a sufficient treatment for opioid addiction (Sees et al. 2000) , but for many individuals, it is the first instance of contact with treatment services and it may facilitate the transition into long-term care (Amato et al. 2004) . In Western medicine, the pharmacological agents most commonly used for detoxification are either opioid agonists or a2-adrenergic agonists (or a combination of the two). Chinese herbal medicine (CHM) is also used for detoxification (Shi et al. 2006; Ghodse et al. 2006) , but most of the controlled clinical trials of CHM have been published in Chinese journals and are not available to English readers. A preliminary meta-analysis of 11 such trials, by Min et al. (2005) , suggested that CHM was more effective than a2-adrenergic agonists and possibly more effective than opioid agonists. Due to the limited number of trials available for review at the time, Min et al. called for further meta-analyses to be performed as more data become available.
Therefore, the aim of our study was to replicate and extend Min et al.'s earlier systematic review and meta-analysis of randomized controlled trials assessing the efficacy and safety of CHM on heroin detoxification. We identified additional trials and, unlike Min et al. (2005) , we separately assessed outcomes for each of the first 10 days of withdrawal rather than reporting a time-averaged outcome measure for each trial.
Methods

Literature Search
We attempted to locate all reports of relevant clinical trials published from January 1990 to August 2007, and we also contacted with experts in the field to find ongoing and unpublished studies. The databases searched included three English databases (EMBASE, PUBMED, and the Cochrane Central Register of Controlled Trials) and four Chinese databases (Chinese Biomedical Literatures, China National Knowledge Infrastructure, Wan Fang, and VIP). The following search terms were used: opioid detoxification, opioid dependence, opioid withdrawal, opiate, heroin, and morphine, along with their Chinese counterparts. Further narrowing of the results was done by reading titles and abstracts rather than via search terms, because nearly 70 different types of CHM are used in drug-dependence treatment. In addition, the reference list from each relevant article was inspected to find other relevant studies.
Inclusion/Exclusion Criteria for Meta-analysis Inclusion criteria: (1) randomized controlled trials for heroin detoxification comparing CHM as the experimental condition and a2-adrenergic agonists or opioid receptor agonists as a control condition; (2) patients diagnosed with opioid dependence or heroin dependence and in the acute stage of abstinence symptoms; (3) demographic and drug-use characteristics of patients reported in detail; (4) at least 15 patients in each group; (5) at least one of the following three outcome measures: total score on the opioidwithdrawal symptoms scale (WSS) , anxiety score (Hamilton Anxiety Scale, HAMA), and rate of adverse effects; (6) WSS were assessed day by day. Exclusion criteria: (1) CHM given only in combination with other medications; (2) results shown only in figures; (3) inconsistencies in reporting of the number of participants; (4) design features that could cause heterogeneity-for example, 3-day medication versus 10-day medication (Zhou et al. 2004b ); (5) trials scoring low in quality (see below for quality-assessment method) that caused significant heterogeneity (Mo et al. 2003) . If a study was reported in more than one publication, only the first version was included. No distinction was made between patients dependent on heroin alone or heroin plus other drugs (such as benzodiazepines).
Data Extraction and Quality Assessment
Two reviewers reviewed the search hits by reading the titles and abstracts and assessed the article for inclusion. Uncertainties were resolved through discussion. For each study, the following key information was extracted: first author, publication year, study design, patients' demographic characteristics, sample size for each intervention, and outcomes.
The methodological quality of the included trials was assessed using the Jadad scale (Jadad et al. 1996) for: (1) randomization, (2) double-blinding, (3) description of withdrawal, (4) description of randomization, (5) description of blinding. Trials scoring 1 or 2 points are considered low quality, trials scoring 3-5 points are considered high quality.
Data Synthesis and Analysis
Demographic information was summarized for all patients in included studies. RevMan software (Cochrane Collaboration 2004) was used for meta-analysis. Continuous outcomes (such as scores on rating scales) were assessed in terms of the weighted mean difference (WMD) between CHM and the control intervention, and 95% confidence intervals (95% CIs) were calculated. Dichotomous outcomes (such as the presence or absence of an adverse effect) were assessed in terms of relative risk (RR) for CHM and the control intervention, and 95% CIs were calculated. Random-effects models were used to analyze pooled effects when heterogeneity was significant otherwise fixed-effects models were used. All pooled analysis was stratified by control interventions: a2-adrenergic agonists and opioid-receptor agonists. Differences were taken to be statistically significant when 95% CIs did not overlap (a more stringent criterion than a significance test at P \ 0.05; Wolfe and Hanley 2002) . Sensitivity analysis was then carried out to assess the influence of study quality on effect estimates and to estimate fail-safe numbers of unpublished negative studies that could overturn the results.
Results
Characteristics of Studies
We found 48 reports of RCTs of Chinese herbal medicine alone versus western medication for heroin detoxification, of which 21 (enrolling 2,949 participants) were eligible for inclusion in the meta-analysis (for detailed information, see Table 1 ). The average age of patients analyzed ranged from 23 to 39 years, and most of them were males (76.8%). The average amount of daily heroin use was 0.09-1.26 g, with duration of use of 7-94 months. Intravenous injection and insufflation were the commonly reported routes of administration.
Twelve studies used a2-adrenergic agonists as a control medication and seven studies used opioid agonists as a control medication; two studies used both (clonidine and methadone). Of the 21 studies, 10 were judged high in quality (scoring 3-5 points).
Eighteen herb formulas were included in the 21 studies; the most frequently used herbs were Radix Ginseng (Renshen) (eight studies), Rhizoma Corydalis (Yanhusuo) (seven studies), Radix Aconiti Lateralis Preparata (Fuzi) (five studies), Radix Glycyrrhizae (Gancao) (five studies), Flos Daturae (Yangjinhua) (four studies), and Radix Angelicae Sinensis (Danggui) (three studies). Sample sizes did not permit separate meta-analytic evaluation of the effect of herb type.
Efficacy of Chinese Medicine
Total score of withdrawal-symptom score (WSS) CHM Versus a2-Adrenergic Agonists Fourteen studies assessed WSS day by day. Of these, nine studies (with 1,042 participants) scored 3-5 on the Jadad scale, and five studies (with 815 participants) scored 1-2. Only the results of the nine high-quality studies are shown in Fig. 1A . Pretreatment baseline scores (D0) were similar across treatments. For the first 3 days (D1-D3), there was no significant difference between CHM and a2-adrenergic agonists. From the fourth day onward (D4-D10), CHM was significantly more effective than a2-adrenergic agonists, except on D8.
CHM Versus Opioid-Receptor Agonists Seven studies involving 593 patients were analyzed (Fig. 1B) ; all were judged relatively low quality (1-2 on the Jadad scale). Again, pretreatment baseline scores (D0) were similar across treatments. For the first 3 days of treatment (D1-D3), CHM was significantly less effective than opioid-receptor agonists. From the fourth day onward, there were no statistically significant differences across treatments, except on D7 and D10, when differences favored CHM.
Anxiety
Most studies estimated anxiety at three time points: before treatment (D0), during treatment (D5), and after treatment (D10). Only studies with at least two time points were included in our analyses.
CHM Versus a2-Adrenergic Agonists Seven studies assessed anxiety. Five studies were judged high quality, and the other two were judged low quality. Six studies (with 978 participants) included pretreatment data, six studies (with 963 participants) included Table 1 Characteristics of included studies Notes: * Outcomes: 1-total score on withdrawal-symptoms scale (WSS); 2-change score on WSS; 3-specific items on WSS; 4-HAMA score; 5-ratings of craving; 6-rate of adverse effects; 7-scoring of adverse effects; 8-blood pressure; 9-heart rate; 10-laboratory exam; 11-number of participants completing detoxification ** Including 2 control groups *** No detailed characteristics of treatment and control groups were listed, and only the merging information of total participants was listed in study of 'Sha et al. (2000) '. And the average age was 28.0; the percent of male was 89.4%
during-treatment data, and seven studies (1135 cases) included end-of-treatment data ( Fig. 2A) . Results at the end of treatment favored CHM. CHM Versus Opioid-Receptor Agonists Two studies (with 685 participants) included pretreatment data, one study (with 105 participants) included during-treatment data, and two studies (with 685 participants) included end-of-treatment data (Fig. 2B) . There was no significant difference between groups at any time point.
Safety of Chinese Medicine: Adverse Effects
Rates of specific adverse effects were reported for nine studies, of which only one used opioid-receptor agonists; therefore, we included only the eight studies using a2-adrenergic agonists. Six studies were judged high quality (3-5 points); the other two were judged low quality (1-2 points). The main side effects reported in these studies were: dry mouth (eight studies, 1,036 patients), dizziness (eight studies, 1,036 patients), blurred vision (seven studies, 983 patients), fatigue (five studies, 723 patients), and somnolence (four studies, 387 patients). Figure 3 shows the relative risks for specific adverse effects with CHM or a2-adrenergic agonists. CHM was less likely to produce reports of fatigue or dizziness; there were no significant differences across treatments for the other commonly reported effects (blurred vision, somnolence, and dry mouth). Fig. 1 Efficacy of Chinese herbal medicine (CHM) compared with a2-adrenergic agonists (A), and opioid agonists (B) in alleviating opioid-withdrawal symptoms. Summary estimates of the weighted mean differences (WMDs) and their 95% CIs are given day by day. D0 indicates pretreatment baseline. D0, D5, D6, D9, D10 in (A) and D0, D1, D2 in (B) were analyzed in fixedeffects models. The other time points were analyzed in randomeffects models. N R indicates the fail-safe number, i.e. the number of unpublished negative studies that would be required to overturn each significant finding at an alpha level of 0.05 Fig. 2 Efficacy of CHM compared with a2-adrenergic agonists (A), and opioid agonists (B) in relieving anxiety. Summary estimates of the weighted mean differences (WMDs) and their 95% CIs are given at three time points. ''Beginning'' and ''End'' in (A) and ''Beginning,'' ''middle,'' and ''End'' in (B) were analyzed in fixed-effects models. The other time points were analyzed in random-effects models. N R indicates the fail-safe number, i.e. the number of unpublished negative studies that would be required to overturn each significant finding at an alpha level of 0.05 Few studies reported the other side effects, such as sagging, instability of gait, dysuria, headache, nausea, and inappetency. Thus, we did not analyze them. But the original data showed the side effects of Chinese herbal medicine were slight or moderate, and most of them disappeared spontaneously without treatment.
Sensitivity Analysis and the File-Drawer Effect
Inclusion or exclusion of the low-quality studies had no effect on the opioid-agonist results, but did affect some of the a2-agonist results, as follows.
Withdrawal-Symptom Scores (WSS)
With the five low-quality a2-agonist studies included (14 studies total), results favored CHM over a2-adrenergic agonists from the first day rather than from only the third day: D1, -3.52 [-5.81, -1.22 ], D2; -4.32 [-6.60, -2.04] . When only the five lowquality studies were included, results were similar to those for all 14 studies: D1, -5.30 [-8.00, -2.61], D2, -6.04 [-9.41, -2.66 ].
Anxiety
The five high-quality a2-agonist studies assessing anxiety showed that the difference in HAMA scores was no longer significant at any of the three time points: beginning, 0.36 [-0.68, 1.40] ; middle, 0.30 [-0.37, 0.98]; end, -0.32 [-0.71, 0.08] . However, the two low-quality studies assessing anxiety favored CHM over a2-adrenergic agonists from the middle time point: beginning, 1.43 [0.31, 2.55]; middle, -1.74 [-2.56, -0.91]; end, -0.72 [-1.20, -0.24] .
Adverse Effects
Results of the six high-quality studies assessing adverse effects were similar to those of all eight studies pooled. However, results of the two lowquality studies assessing adverse effects showed no significant difference between Chinese medicine and a2-agonist treatment except for somnolence (one study, 99 cases): 0.02 [0.00, 0.11].
To address the ''file-drawer problem'' (the possibility of unpublished negative studies that would negate the findings of the published studies), we calculated the fail-safe number N R (Rosenthal 1979), representing the number of studies with null results that would be necessary to render each of our findings non-significant at P = 0.05. N R s are shown in the rightmost portions of Figs. 1, 2, and 3. Note that N R s are calculated in terms of significant differences at P = 0.05, which sometimes emerge even in instances when 95% CIs overlap (Wolfe and Hanley 2002) .
Discussion
Our meta-analysis shows that CHM was superior to a2-adrenergic agonists in relieving opioid-withdrawal symptoms during 4-10 days (except D8). Compared with opioid agonists, CHM was inferior during the first 3 days, but the difference became non-significant during days 4-9 (except D7). During the first 3 days of opioid abstinence that has been considered as the critical stage of withdrawal-symptom management, CHM has the same effectiveness with a2-adrenergic agonists but inferior to opioid agonists in relieving opioid-withdrawal symptoms. Anxiety may be of motivational relevance for the maintenance of addiction (Schulteis et al. 1998) . CHM has better effect on anxiety relieving at late stage of intervention than a2-adrenergic agonists, and no difference with opioid agonists. The incidence of adverse effects (fatigue, dizziness) was significantly lower for CHM than for a2-adrenergic agonists (sufficient data for comparison with opioid agonists were not available).
Sensitivity analyses showed that when only highquality studies were included in the meta-analyses, the advantage for CHM on one outcome measure (anxiety reduction, CHM, versus a2-adrenergic agonists) was lost. However, the bulk of the other findings remained the same. When differences were significant, fail-safe numbers were high, often in the hundreds, strongly suggesting that our findings did not merely reflect publication bias in favor of CHM.
Our findings differ somewhat from those of the earlier meta-analysis we had sought to replicate and extend (Min et al. 2005) in which CHM had appeared to be superior to methadone for relief of withdrawal symptoms. In the earlier meta-analysis, this comparison relied on only three trials (706 cases); our finding relied on nine randomized trials (1,278 cases) and thus seems more likely to be reliable.
CHM in the treatment of drug dependence has a long history and a complex doctrinal basis (Li et al. 2005 ). However, only in the last 20 years has it been assessed with well-designed clinical trials. On the basis of such trials, some forms of CHM have already been approved by the Chinese State Food and Drug Administration (SFDA) for use in addiction treatment, and clinical trials of another six forms are in progress (Shi et al. 2006) . The forms of CHM included in this meta-analysis included both SFDAapproved and non-approved herbs. Traditional herbal medicine is also being systematically tested for addiction treatment in India, Thailand, Iran, and elsewhere (Alper et al. 1999 (Alper et al. , 2000 Akhondzadeh et al. 2001) .
Of the six herbs most frequently used in the studies in our meta-analysis, five (all except Radix Aconiti Lateralis Preparata) are among the top ten most frequently used to treat addiction in China . Preclinical work has demonstrated the actions of some of these herbs on the behavioral effects of abused drugs (e.g. Takahashi and Tokuyama 1998) and has begun to clarify the actions of their main active constituents (e.g. Mantsch et al. 2007 ). However, such work remains in its early stages.
Our meta-analysis had some limitations. Most important, interventions and outcome measures both had to be lumped together more than would be ideal. Different CHM preparations presumably have different mechanisms of action and may be differentially effective against specific symptoms of heroin withdrawal; we were unable to assess this. We were also unable to examine the influence of duration/severity of heroin dependence, though we suspect that CHM alone is probably not adequate to manage withdrawal in the most severely addicted patients (Shi et al. 2006) . The clinical trials we assessed involved only detoxification; in future studies, CHM needs to be evaluated for relapse prevention (Shi et al. 2006) . Some of the lowerquality trials included in our main analyses did not contain adequate details about blinding. All included trials were conducted in China, so results may not be generalizable to other regions. We were unable to pool all the reported adverse-effect data due to its heterogeneity (some studies reported data on blood pressure, heart rate, and liver and kidney function; no adverse effects of CHM appeared to emerge). Finally, not all forms of CHM thought to have potential for opioidaddiction treatment were included in this analysis.
However, this meta-analysis represents the first time that the results of some of these studies are readily available to an English-language readership. We found that CHM, while not as effective as opioid agonists, does compare favorably to a2-adrenergic agonists in relieving abstinence symptoms and perhaps in relieving anxiety during managed withdrawal from heroin, and that CHM's side-effect profile appears more benign than that of a2-adrenergic agonists. More well-designed clinical trials are needed to enable conclusions about specific forms of CHM and to determine for which patients it is most likely to be appropriate.
